Single-Use Technologies for the Biologic Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Membrane Adsorber, Bioreactors, Disposable Mixing Systems, Tangential Flow Filtration, Tubing and Connectors, Depth Filtration, Buffer Containers, Waste Containers), By Applications (Monoclonal Antibodies, Vaccines, Gene Therapy, Recombinant Proteins, Blood Derivatives), Regional Insights and Forecast to 2035
- Last Updated: 23-October-2026
- Base Year: 2025
- Historical Data: 2021 - 2024
- Region: Global
- Format: PDF
- Report ID: GGI108271
- SKU ID: 30553171
- Pages: 109
Download FREE Sample
Single-Use Technologies for the Biologic Market Size
The global Single-Use Technologies for the Biologic Market was valued at USD 11994.8 Million in 2025 and is expected to reach USD 13416.12 Million in 2026 and USD 15006 Million in 2027, before climbing to USD 36751.98 Million by 2035. This reflects a CAGR of 11.85% across the 2026-2035 forecast period.
Demand is shaped less by any single product and more by how biologics are now manufactured. Drug makers favor disposable fluid paths because they remove cleaning validation and shorten changeover. Roughly 70% of clinical-stage biologic batches now run on at least one single-use unit operation. Bioreactors and filtration formats together account for close to 33% of installed disposable assemblies. As pipelines split into smaller, multi-product campaigns, flexibility has become the deciding purchase criterion.
![]()
In the US Single-Use Technologies for the Biologic Market, adoption is shaped by a dense cluster of contract manufacturers and clinical-stage developers. The country accounts for about 82% of North American demand, and nearly 55% of its biologic production sites already run hybrid or fully disposable suites, which keeps consumable replenishment steady.
Key Findings
- Market Size: Starting at $13416.12M in 2026, projected to touch $15006M in 2027 to $36751.98M by 2035 at a CAGR of 11.85%.
- Growth Drivers: Over 60% of new biologic facilities adopt single-use platforms, with 30% faster batch turnaround and 25% lower cross-contamination risk.
- Trends: Roughly 45% of process developers favor intensified workflows, and 35% of installations pair disposable assemblies with automated sensors.
- Key Players: Thermo Fisher Scientific, Sartorius, Pall, GE Healthcare, EMD Millipore & more.
- Regional Insights: North America leads with 38% share, Europe holds 29%, Asia-Pacific captures 24%, and Middle East & Africa contributes 9%, reflecting mature capacity in the West and fast build-out in emerging hubs.
- Challenges: Extractables concerns touch nearly 28% of qualification projects, while single-source supply exposure affects about 33% of critical components.
- Industry Impact: Disposable formats cut water and cleaning demand by about 80% and shorten facility setup timelines by nearly 40%.
- Recent Developments: Around 20% of recent capacity additions targeted single-use filtration and bioreactors, with about 15% focused on closed-system connectors.
Consumables, rather than hardware, drive recurring demand here, because every batch consumes fresh bags, filters, and connectors. Roughly 75% of supplier activity centers on replenishable items, which gives manufacturers dependable visibility and ties customers to validated product families.
Qualification effort acts as a quiet moat. About 40% of users hesitate to switch suppliers once a process is validated, which protects incumbents while newer entrants concentrate on interoperability and standardized interfaces.
![]()
Single-Use Technologies for the Biologic Market Trends
Process intensification is rewriting equipment specifications. Perfusion and high-density cell culture now feature in about 40% of new upstream designs, and these workflows consume disposable assemblies at a faster rate than traditional fed-batch runs. Manufacturers are responding with larger-format bags, pre-integrated manifolds, and tighter sensor integration. Around 35% of newly commissioned disposable trains ship with embedded monitoring for pH, dissolved oxygen, and pressure, so operators can see deviations before a batch is compromised.
A second shift is the move toward fully closed, ready-to-use fluid paths. Pre-sterilized, pre-assembled kits now represent close to 50% of purchasing decisions among mid-sized biologic developers, who lack the in-house staff to assemble and validate custom configurations. Sustainability is also entering procurement conversations: roughly 30% of buyers now ask suppliers about recycling or take-back options for polymer waste. Together these shifts push the industry toward standardized, interoperable components and away from bespoke engineering, which favors vendors with broad portfolios.
Single-Use Technologies for the Biologic Market Dynamics
Growth in cell and gene therapy and decentralized manufacturing
Cell and gene therapy programs rely on small, patient-specific or low-volume batches where cleaning stainless steel equipment makes little economic sense. Around 65% of advanced therapy developers already select disposable fluid paths for early-phase production, and this preference tends to carry forward into commercial scale. Regional and decentralized manufacturing models add further room for expansion, since compact single-use suites can be commissioned about 35% faster than conventional facilities. Suppliers that offer validated, modular kits for viral vector production and cell expansion stand to win repeat consumable orders over the long product lifecycle of each therapy.
Rising adoption of disposable biomanufacturing platforms
Biologic producers are replacing fixed infrastructure with disposable systems to gain speed and reduce contamination risk. Eliminating clean-in-place and steam-in-place routines lowers water and chemical use by roughly 80%, while changeover between campaigns can fall by close to 50%. These gains matter most as monoclonal antibody and vaccine pipelines multiply and facilities must run several products in parallel. About 60% of new biologic plants now specify single-use equipment at the design stage, which locks in recurring demand for bags, filters, tubing, and connectors throughout the operating life of each site.
| Market Driver | Impact Rank | Contribution | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Shift to disposable biomanufacturing platforms | High | 4.8% | High | High | Medium |
| Expanding monoclonal antibody and vaccine pipelines | High | 3.9% | High | High | Medium |
| Scale-up of cell and gene therapy production | Medium | 2.8% | Medium | High | High |
| Outsourcing to contract manufacturing organizations | Medium | 1.9% | Medium | Medium | Low |
| Process intensification and closed-system automation | Low | 1.0% | Low | Medium | High |
| Others | Lowest | 0.6% | Low | Low | Low |
| Total Driver Contribution | 15.0% |
RESTRAINTS
"Qualification burden around extractables and leachables"
Every polymer component that touches a biologic product must be assessed for substances that could migrate into the drug stream. This testing adds time and cost, and roughly 28% of single-use qualification projects need extra studies after the first round of results. Smaller developers feel the strain most, as they often lack dedicated analytical teams. Dependence on a narrow group of resin and film suppliers compounds the issue, since about 33% of critical components come from a single qualified source. Together these factors slow adoption in regulated, late-stage programs and limit how aggressively some manufacturers can switch from stainless steel.
| Market Restraint | Impact Rank | Negative CAGR Impact | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Extractables and leachables qualification burden | High | -1.5% | High | High | Medium |
| Supply concentration for polymer components | Medium | -1.0% | Medium | Medium | Low |
| Plastic waste and sustainability pressure | Low | -0.45% | Low | Medium | Medium |
| Others | Lowest | -0.2% | Low | Low | Low |
| Total Restraint Impact | -3.15% |
CHALLENGES
"Waste handling and process standardization"
Disposable processing generates plastic waste at a rate that sustainability teams cannot ignore. Single-use components can account for roughly 30% of the solid waste produced inside a biologic plant, and recycling routes for medical-grade polymers remain limited. Standardization is a parallel difficulty. Connector and bag formats still differ across suppliers, and around 25% of manufacturers report integration problems when mixing components from several vendors. Closing these gaps requires collaboration on interface standards and credible end-of-life programs, both of which take time to mature.
Segmentation Analysis
The market is segmented by product type and by the biologic class each system serves. Upstream and fluid-management formats such as bioreactors and mixing systems carry the largest weight, while downstream purification products grow in step with rising titers. On the application side, monoclonal antibodies dominate volumes, though gene therapy and vaccines expand faster than the overall market because their small-batch, high-purity demands suit disposable platforms. Across all segments, about 80% of consumable demand is recurring rather than one-off capital purchasing.
By Type
Membrane Adsorber
Membrane adsorbers hold about 10% of the market and are gaining ground in polishing steps where flow-through operation matters. Their convective transport allows loading speeds up to 5 times faster than packed-bed resins in many impurity and viral clearance tasks. Because they arrive pre-assembled and ready to use, they trim buffer consumption by roughly 30%, which appeals to facilities running short campaigns for monoclonal antibodies and gene therapy vectors.
Bioreactors
Single-use bioreactors lead the type landscape with close to 18% share, anchored by their role at the heart of upstream cell culture. Roughly 60% of new mammalian cell culture suites are specified with disposable vessels instead of stainless steel. Turnaround between batches is typically 25% shorter, and lower capital intensity keeps developers and contract manufacturers returning for additional vessel capacity as pipelines widen.
Disposable Mixing Systems
Disposable mixing systems represent near 15% of demand and underpin buffer, media, and formulation preparation. Pre-sterilized bags with standardized drive units reduce preparation errors by about 20% and remove most cleaning steps between lots. Adoption is especially strong among contract manufacturers, where around 65% of buffer preparation lines now rely on disposable mixers to handle frequent product changes without extended downtime.
Tangential Flow Filtration
Tangential flow filtration assemblies account for about 14% of the market and are central to concentration and diafiltration of proteins and vaccines. Roughly 45% of downstream sequences include at least one such step. Single-use cassettes and flow paths cut changeover time by close to 50% and largely eliminate carryover concerns, a decisive benefit for facilities that switch between products several times a year.
Tubing and Connectors
Tubing and connectors make up roughly 13% of the market and appear in virtually every disposable train. Sterile connection technologies reduce open-handling steps by about 40%, lowering contamination exposure during transfers. Demand tracks the installed base of bioreactors and mixers closely, and replenishment orders represent around 70% of unit volume, which gives this segment a steady, repeat-driven profile.
Depth Filtration
Depth filtration captures about 11% of demand and is essential for harvest clarification. As cell culture titers climb, filters face roughly 20% heavier particulate burden, pushing suppliers toward higher-capacity media. Around 50% of clarification trains now use disposable depth filter capsules, valued for fast installation and the absence of housing cleaning and validation requirements.
Buffer Containers
Buffer containers hold close to 11% share and serve as the storage backbone of downstream processing. Intensified workflows use about 30% more bags per process because buffer volumes multiply across continuous steps. Standardized two-dimensional and three-dimensional bags shrink storage footprints by nearly 35% compared with fixed tanks, a clear advantage for space-constrained facilities.
Waste Containers
Waste containers represent the smallest type segment at about 8%, yet they matter for closed, safe handling of spent media and process effluent. Containment-focused designs help cut operator exposure incidents by roughly 25% in biosafety-sensitive operations. Growth is supported by sustainability programs, with around 20% of buyers now evaluating collection formats compatible with recycling or inactivation workflows.
By Application
Monoclonal Antibodies
Monoclonal antibodies account for about 46% of application demand, making them the anchor use case for disposable systems. High-volume cell culture, repeated purification cycles, and frequent product changeovers all favor single-use formats. Roughly 70% of antibody facilities built recently are designed around disposable upstream and downstream equipment, and platform processes allow suppliers to standardize kits across multiple molecules.
Vaccines
Vaccines represent close to 21% of the market, supported by the need for rapid, flexible capacity. Disposable systems allow producers to repurpose suites about 40% faster between antigens or strains, which matters during seasonal and outbreak-driven campaigns. Closed-system processing also reduces contamination risk in live and viral-vector vaccine production, where containment is a priority for roughly 60% of manufacturers.
Gene Therapy
Gene therapy holds about 14% of application demand and is among the fastest expanding areas. Viral vector production runs at small scale with strict purity requirements, so around 75% of developers choose disposable bioreactors and filtration assemblies from the outset. Lower upfront investment and quicker facility readiness help early-stage companies advance candidates without building fixed infrastructure.
Recombinant Proteins
Recombinant proteins contribute roughly 12% of the market and cover hormones, enzymes, and other therapeutic proteins. Batch sizes are moderate, and multi-product plants value the flexibility of disposable mixing and filtration, with about 55% of such facilities operating hybrid setups. Reduced cleaning validation shortens campaign gaps by close to 30%, improving asset utilization for mid-sized producers.
Blood Derivatives
Blood derivatives account for about 7% of demand and represent a smaller but dependable niche. Plasma fractionation has traditionally relied on fixed equipment, yet disposable filtration and container systems are gaining acceptance, now used in roughly 35% of newer fractionation lines. The appeal lies in lower cross-contamination risk and simplified handling of sensitive protein fractions.
![]()
Single-Use Technologies for the Biologic Market Regional Outlook
Regional demand follows the geography of biologic manufacturing capacity, regulatory maturity, and investment in new facilities. North America holds 38% of global share, Europe accounts for 29%, Asia-Pacific represents 24%, and Middle East & Africa contributes 9%, together making up the full market. Mature regions prioritize optimization and process intensification, while emerging regions focus on building first-generation capacity, and about 60% of new site announcements outside the West specify disposable equipment from the outset.
North America
North America commands 38% of the market, supported by a deep base of biologic developers, contract manufacturers, and advanced therapy companies. Around 55% of regional production sites operate hybrid or fully disposable suites. Strong clinical pipelines and a high concentration of platform processes keep consumable demand stable, and roughly 30% of regional buyers are now adopting integrated sensors and automation to improve batch consistency.
Europe
Europe holds 29% of global share, driven by established biopharmaceutical clusters and strict quality expectations. Roughly 50% of regional biologic facilities use single-use technology in at least one major process stage. Sustainability regulation is shaping purchasing, with about 35% of European buyers prioritizing suppliers offering recycling or waste reduction programs, which pushes manufacturers toward lower-polymer designs and take-back initiatives.
Asia-Pacific
Asia-Pacific represents 24% of the market and is the fastest-growing region, expanding at a pace well above the global average. New biologic and biosimilar capacity is being added across several economies, and roughly 65% of greenfield projects specify disposable systems to speed commissioning. Government support for domestic biologic production and rising contract manufacturing activity strengthen long-term consumable demand.
Middle East & Africa
Middle East & Africa accounts for 9% of the market, anchored by growing investment in local vaccine and biologic production. Disposable systems suit the region because they lower infrastructure and water requirements, and about 45% of planned facilities are designed around modular single-use suites. Partnerships with established suppliers help transfer technical knowledge, supporting gradual capacity development.
List of Key Single-Use Technologies for the Biologic Market Companies Profiled
- Thermo Fisher Scientific
- Applikon Biotechnology
- GE Healthcare
- Pall
- BioPure Technology
- Sartorius
- Novasep
- W. L. Gore and Associates
- EMD Millipore
- DowDuPont
Top Companies with Highest Market Share
- Thermo Fisher Scientific: Holds about 16% market share, supported by a broad portfolio of bioreactors, containers, and fluid-management assemblies.
- Sartorius: Commands roughly 14% share, led by strong positions in filtration, mixing systems, and disposable bioprocess consumables.
Investment Analysis and Opportunities
Capital is flowing toward capacity that can be commissioned quickly and repurposed easily. Roughly 55% of recent biomanufacturing investment decisions favor modular or flexible facilities, and disposable equipment is specified in most of them because it reduces upfront build requirements by around 30%. Contract manufacturers are especially active, with about 40% planning to expand single-use suites to serve small and mid-sized biologic developers. Opportunities also sit in component supply: filtration media, sterile connectors, and sensor-equipped bags attract steady interest because they generate repeat orders. Suppliers that invest in regional manufacturing, validated documentation packages, and recyclable material options are well placed, since about 35% of buyers now weigh supply security and sustainability alongside price.
New Products Development
Product development is concentrating on integration, capacity, and cleaner materials. About 45% of recent launches combine several unit operations into pre-assembled, ready-to-use kits that reduce setup time and connection points. Larger bioreactor formats and higher-capacity filters respond to rising titers, while embedded sensors appear in roughly 35% of newly introduced bags and vessels. Material science is another focus: low-extractable films and improved resin formulations aim to ease qualification, and around 25% of new introductions highlight reduced polymer content or recyclability. Suppliers are also refining aseptic connectors and automated fluid-handling modules, helping customers lower manual intervention by close to 40% in closed processing workflows.
Recent Developments
- March 2024– Sartorius expanded single-use filtration and fluid management output: The company increased production capacity for disposable filters and bag assemblies to meet demand from antibody and vaccine producers. The addition raised available output for these lines by roughly 20%, shortening delivery lead times and improving supply security for customers running continuous campaigns.
- August 2024– Thermo Fisher Scientific broadened its disposable bioprocess container range: The portfolio update introduced additional bag formats and pre-assembled configurations aimed at buffer and media handling. Early customer evaluations indicated setup time reductions of about 30%, strengthening the appeal of ready-to-use kits for mid-sized biologic developers.
- January 2025– Pall advanced integrated filtration and closed connection assemblies: The initiative combined filtration capsules with sterile connection features to limit open handling during transfers. The design reduced manual connection steps by around 35%, supporting contamination control in downstream purification for gene therapy and recombinant protein workflows.
- May 2025– Applikon Biotechnology upgraded single-use bioreactor control capabilities: The refreshed systems added improved monitoring and automated adjustment for small and mid-scale cell culture. Users reported roughly 15% better batch-to-batch consistency, which matters for cell and gene therapy developers moving candidates toward clinical production.
- September 2025– Novasep strengthened disposable purification solutions for biologics: The company expanded its single-use offerings for downstream steps, targeting facilities that need faster changeover between products. The enhancements cut cleaning-related downtime by nearly 40% in pilot configurations and widened options for multi-product purification suites.
Report Coverage
This report examines the Single-Use Technologies for the Biologic Market through its structure, demand drivers, restraints, opportunities, and competitive landscape. It segments the market by type, including membrane adsorbers, bioreactors, disposable mixing systems, tangential flow filtration, tubing and connectors, depth filtration, buffer containers, and waste containers, and by application across monoclonal antibodies, vaccines, gene therapy, recombinant proteins, and blood derivatives. Share distribution is analyzed for each segment, with bioreactors leading types at about 18% and monoclonal antibodies leading applications at roughly 46%. Regional coverage spans North America at 38%, Europe at 29%, Asia-Pacific at 24%, and Middle East & Africa at 9%. The competitive review profiles ten manufacturers, assessing portfolio breadth, capacity moves, and product development focus, with the two largest players together holding close to 30% of the market. The study also evaluates investment patterns, new product activity, and recent corporate developments, giving manufacturers, investors, and procurement teams a practical view of how disposable technologies are reshaping biologic production.
Single-Use Technologies for the Biologic Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 13416.12 Million in 2026 |
|
|
Market Size Value By |
USD 36751.98 Million by 2035 |
|
|
Growth Rate |
CAGR of 11.85% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Download FREE Sample
Frequently Asked Questions
-
What value is the Single-Use Technologies for the Biologic Market expected to touch by 2035?
The global Single-Use Technologies for the Biologic Market is expected to reach USD 36751.98 Million by 2035.
-
What CAGR is the Single-Use Technologies for the Biologic Market expected to exhibit by 2035?
The Single-Use Technologies for the Biologic Market is expected to exhibit a CAGR of 11.85% by 2035.
-
Who are the top players in the Single-Use Technologies for the Biologic Market?
Thermo Fisher Scientific, Applikon Biotechnology, GE Healthcare, Pall, BioPure Technology, Sartorius, Novasep, W. L. Gore and Associates, EMD Millipore, DowDuPont
-
What was the value of the Single-Use Technologies for the Biologic Market in 2025?
In 2025, the Single-Use Technologies for the Biologic Market value stood at USD 11994.8 Million.
About the Author(s):
This report was authored by the Healthcare Research Team at Global Growth Insights. The team specializes in pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, healthcare services, and life sciences. Their expertise includes market sizing, regulatory analysis, competitive benchmarking, and healthcare trend forecasting to support strategic investment and business growth.
Our Clients
Download FREE Sample